High‐Titer Hepatitis C Virus Production in a Scalable Single‐Use High Cell Density Bioreactor

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

High‐Titer Hepatitis C Virus Production in a Scalable Single‐Use High Cell Density Bioreactor. / Offersgaard, Anna; Duarte Hernandez, Carlos Rene; Finne Pihl, Anne; Prabhakar Venkatesan, Nandini; Krarup, Henrik; Lin, Xiangliang; Reichl, Udo; Bukh, Jens; Genzel, Yvonne; Gottwein, Judith Margarete.

I: Vaccines, Bind 10, Nr. 2, 249, 2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Offersgaard, A, Duarte Hernandez, CR, Finne Pihl, A, Prabhakar Venkatesan, N, Krarup, H, Lin, X, Reichl, U, Bukh, J, Genzel, Y & Gottwein, JM 2022, 'High‐Titer Hepatitis C Virus Production in a Scalable Single‐Use High Cell Density Bioreactor', Vaccines, bind 10, nr. 2, 249. https://doi.org/10.3390/vaccines10020249

APA

Offersgaard, A., Duarte Hernandez, C. R., Finne Pihl, A., Prabhakar Venkatesan, N., Krarup, H., Lin, X., Reichl, U., Bukh, J., Genzel, Y., & Gottwein, J. M. (2022). High‐Titer Hepatitis C Virus Production in a Scalable Single‐Use High Cell Density Bioreactor. Vaccines, 10(2), [249]. https://doi.org/10.3390/vaccines10020249

Vancouver

Offersgaard A, Duarte Hernandez CR, Finne Pihl A, Prabhakar Venkatesan N, Krarup H, Lin X o.a. High‐Titer Hepatitis C Virus Production in a Scalable Single‐Use High Cell Density Bioreactor. Vaccines. 2022;10(2). 249. https://doi.org/10.3390/vaccines10020249

Author

Offersgaard, Anna ; Duarte Hernandez, Carlos Rene ; Finne Pihl, Anne ; Prabhakar Venkatesan, Nandini ; Krarup, Henrik ; Lin, Xiangliang ; Reichl, Udo ; Bukh, Jens ; Genzel, Yvonne ; Gottwein, Judith Margarete. / High‐Titer Hepatitis C Virus Production in a Scalable Single‐Use High Cell Density Bioreactor. I: Vaccines. 2022 ; Bind 10, Nr. 2.

Bibtex

@article{e2712368855041369ee068f40e618982,

title = "High‐Titer Hepatitis C Virus Production in a Scalable Single‐Use High Cell Density Bioreactor",

abstract = "Hepatitis C virus (HCV) infections pose a major public health burden due to high chronicity rates and associated morbidity and mortality. A vaccine protecting against chronic infection is not available but would be important for global control of HCV infections. In this study, cell culture‐based HCV production was established in a packed‐bed bioreactor (CelCradle{\texttrademark}) aiming to further the development of an inactivated whole virus vaccine and to facilitate virological and immunological studies requiring large quantities of virus particles. HCV was produced in human hepatoma‐derived Huh7.5 cells maintained in serum‐free medium on days of virus harvesting. Highest virus yields were obtained when the culture was maintained with two medium exchanges per day. However, increasing the total number of cells in the culture vessel negatively impacted infectivity titers. Peak infectivity titers of up to 7.2 log10 focus forming units (FFU)/mL, accumulated virus yields of up to 5.9 × 1010 FFU, and a cell specific virus yield of up to 41 FFU/cell were obtained from one CelCradle{\texttrademark}. CelCradle{\texttrademark}‐derived and T flask‐derived virus had similar characteristics regarding neutralization sensitivity and buoyant density. This packed‐bed tide‐motion system is available with larger vessels and may thus be a promising platform for large‐scale HCV production.",

keywords = "CelCradle{\texttrademark}, HCV vaccine development, High cell density cell culture, High‐titer HCV production, Huh7.5 cells, Inactivated virus vaccine, Packed‐bed bioreactor, Whole virus vaccine",

author = "Anna Offersgaard and {Duarte Hernandez}, {Carlos Rene} and {Finne Pihl}, Anne and {Prabhakar Venkatesan}, Nandini and Henrik Krarup and Xiangliang Lin and Udo Reichl and Jens Bukh and Yvonne Genzel and Gottwein, {Judith Margarete}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

doi = "10.3390/vaccines10020249",

language = "English",

volume = "10",

journal = "Vaccines",

issn = "2076-393X",

publisher = "MDPI AG",

number = "2",

}

RIS

TY - JOUR

T1 - High‐Titer Hepatitis C Virus Production in a Scalable Single‐Use High Cell Density Bioreactor

AU - Offersgaard, Anna

AU - Duarte Hernandez, Carlos Rene

AU - Finne Pihl, Anne

AU - Prabhakar Venkatesan, Nandini

AU - Krarup, Henrik

AU - Lin, Xiangliang

AU - Reichl, Udo

AU - Bukh, Jens

AU - Genzel, Yvonne

AU - Gottwein, Judith Margarete

PY - 2022

Y1 - 2022

N2 - Hepatitis C virus (HCV) infections pose a major public health burden due to high chronicity rates and associated morbidity and mortality. A vaccine protecting against chronic infection is not available but would be important for global control of HCV infections. In this study, cell culture‐based HCV production was established in a packed‐bed bioreactor (CelCradle™) aiming to further the development of an inactivated whole virus vaccine and to facilitate virological and immunological studies requiring large quantities of virus particles. HCV was produced in human hepatoma‐derived Huh7.5 cells maintained in serum‐free medium on days of virus harvesting. Highest virus yields were obtained when the culture was maintained with two medium exchanges per day. However, increasing the total number of cells in the culture vessel negatively impacted infectivity titers. Peak infectivity titers of up to 7.2 log10 focus forming units (FFU)/mL, accumulated virus yields of up to 5.9 × 1010 FFU, and a cell specific virus yield of up to 41 FFU/cell were obtained from one CelCradle™. CelCradle™‐derived and T flask‐derived virus had similar characteristics regarding neutralization sensitivity and buoyant density. This packed‐bed tide‐motion system is available with larger vessels and may thus be a promising platform for large‐scale HCV production.

AB - Hepatitis C virus (HCV) infections pose a major public health burden due to high chronicity rates and associated morbidity and mortality. A vaccine protecting against chronic infection is not available but would be important for global control of HCV infections. In this study, cell culture‐based HCV production was established in a packed‐bed bioreactor (CelCradle™) aiming to further the development of an inactivated whole virus vaccine and to facilitate virological and immunological studies requiring large quantities of virus particles. HCV was produced in human hepatoma‐derived Huh7.5 cells maintained in serum‐free medium on days of virus harvesting. Highest virus yields were obtained when the culture was maintained with two medium exchanges per day. However, increasing the total number of cells in the culture vessel negatively impacted infectivity titers. Peak infectivity titers of up to 7.2 log10 focus forming units (FFU)/mL, accumulated virus yields of up to 5.9 × 1010 FFU, and a cell specific virus yield of up to 41 FFU/cell were obtained from one CelCradle™. CelCradle™‐derived and T flask‐derived virus had similar characteristics regarding neutralization sensitivity and buoyant density. This packed‐bed tide‐motion system is available with larger vessels and may thus be a promising platform for large‐scale HCV production.

KW - CelCradle™

KW - HCV vaccine development

KW - High cell density cell culture

KW - High‐titer HCV production

KW - Huh7.5 cells

KW - Inactivated virus vaccine

KW - Packed‐bed bioreactor

KW - Whole virus vaccine

U2 - 10.3390/vaccines10020249

DO - 10.3390/vaccines10020249

M3 - Journal article

C2 - 35214707

AN - SCOPUS:85124391880

VL - 10

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 2

M1 - 249

ER -

ID: 298634703